{"id":1018717,"date":"2026-11-09T08:58:22","date_gmt":"2026-11-09T13:58:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/"},"modified":"2026-11-09T08:58:22","modified_gmt":"2026-11-09T13:58:22","slug":"monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/","title":{"rendered":"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WILMETTE, Ill., Nov.  09, 2026  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation of baseline data from the Phase 3 FoCus trial characterizing residual disease burden in treatment-experienced patients with Wilson disease, along with molybdenum balance and long-term uric acid data for ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting<sup>\u00ae<\/sup> 2026, held Nov. 5\u20139, 2026, in Denver, Colorado.<\/p>\n<p align=\"justify\">Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program at the University of Michigan Health System, delivered an oral presentation of baseline findings from the Phase 3 FoCus study, the largest randomized controlled trial ever conducted in Wilson disease. Key findings included:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt\">Hepatic, neurologic, and psychiatric disease burden was common in both treatment-experienced and treatment-na\u00efve patients at baseline: cirrhosis in 39% and 30%, neurologic symptoms in 79% and 83%, and psychiatric symptoms in 75% and 70%, respectively.<\/li>\n<li style=\"margin-bottom:4pt\">Nearly three-quarters (73%) of evaluable patients had at least two of the following at baseline: cirrhosis, neurologic symptoms, or psychiatric symptoms.<\/li>\n<li style=\"margin-bottom:4pt\">Fewer than half (47%) of treatment-experienced patients were within the guideline-recommended copper target range at baseline.<\/li>\n<li style=\"margin-bottom:4pt\">Nearly a third (31%) of patients receiving standard-of-care therapy for more than 12 months had 24-hour urinary copper excretion above the guideline-recommended copper target range.<\/li>\n<\/ul>\n<p align=\"justify\">\u201cThe substantial disease burden at baseline was striking in both treatment-na\u00efve and treatment-experienced patients. Notably, approximately 80% of patients in both groups had neurologic symptoms, despite treatment-experienced patients having received standard-of-care therapy for a median of more than nine years,\u201d said Dr. Askari. \u201cThe findings also highlighted the frequent overlapping hepatic, neurologic, and psychiatric manifestations in both groups. Having this level of detail from the largest randomized controlled trial conducted in Wilson disease gives clinicians a clearer picture of the disease burden patients continue to carry.\u201d<\/p>\n<p align=\"justify\">Additionally, Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., presented a poster reporting neutral molybdenum balance and lack of molybdenum toxicity in subjects treated with ALXN1840, with serum uric acid remaining within normal limits over six years of treatment. These findings are consistent with ALXN1840\u2019s known albumin tripartite complex (ATC) mechanism and provide further evidence supporting its long-term safety profile.<\/p>\n<p align=\"justify\">The abstracts are available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LWGbxbdaneh6I8k6bxJuumpO4skV6tQMV7fDB-fUelBC4-f9Q7Uvm2_ErpOBUIjPkcTkCk8A447ImQJwqlDReX7w-toDsBpe4VnUwabvE2rPS2WVxawT8Vr1BL6WZNQmR1o25iTyDRJC_8JrrGMTfIAp5WQqpy9teUPr2OANn7U=\" rel=\"nofollow\" target=\"_blank\">AASLD conference website<\/a>. Copies of the presentations are available in the Investors section of Monopar\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fCz4uWyQQGok97AzBYR7Lwf66puAWEoBXMnrJqiopTCFGqIHBLJlMhCHpLlGQv4LUpU4x73G2ts9SW2jDOdyXZswGxRvU-fIIXJq3rkhORw=\" rel=\"nofollow\" target=\"_blank\">www.monopartx.com<\/a>.<\/p>\n<p>\n        <strong>About Wilson Disease<\/strong>\n      <\/p>\n<p align=\"justify\">Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. Caused by mutations in the ATP7B gene, the disease impairs the body\u2019s ability to excrete copper, resulting in toxic copper accumulation in the liver, brain, and other organs and potentially fatal outcomes if untreated.<\/p>\n<p>\n        <strong>About ALXN1840<\/strong>\n      <\/p>\n<p align=\"justify\">ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood\u2013brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.<\/p>\n<p>\n        <strong>About Monopar Therapeutics Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage candidate ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to, uncertainties related to the regulatory and approval process for ALXN1840, and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar\u2019s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>Monopar Therapeutics Inc.<br \/>Investor Relations<br \/>Quan Vu<br \/>Chief Financial Officer<br \/>vu@monopartx.com<\/p>\n<p>Follow Monopar on social media for updates:<br \/>X: @MonoparTx | LinkedIn: Monopar Therapeutics<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmRiZDE1MGItYjMyMC00NWU3LWI4NmItZTkyN2JiMmNjY2NiLTEyMDU0MTYtMjAyNi0xMS0wOS1lbg==\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation of baseline data from the Phase 3 FoCus trial characterizing residual disease burden in treatment-experienced patients with Wilson disease, along with molybdenum balance and long-term uric acid data for ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting\u00ae 2026, held Nov. 5\u20139, 2026, in Denver, Colorado. Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program at the University of Michigan Health &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018717","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation of baseline data from the Phase 3 FoCus trial characterizing residual disease burden in treatment-experienced patients with Wilson disease, along with molybdenum balance and long-term uric acid data for ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting\u00ae 2026, held Nov. 5\u20139, 2026, in Denver, Colorado. Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program at the University of Michigan Health &hellip; Continue reading &quot;Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T13:58:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026\",\"datePublished\":\"2026-11-09T13:58:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/\"},\"wordCount\":881,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/\",\"name\":\"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=\",\"datePublished\":\"2026-11-09T13:58:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026 - Market Newsdesk","og_description":"WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation of baseline data from the Phase 3 FoCus trial characterizing residual disease burden in treatment-experienced patients with Wilson disease, along with molybdenum balance and long-term uric acid data for ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting\u00ae 2026, held Nov. 5\u20139, 2026, in Denver, Colorado. Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program at the University of Michigan Health &hellip; Continue reading \"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T13:58:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026","datePublished":"2026-11-09T13:58:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/"},"wordCount":881,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/","name":"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=","datePublished":"2026-11-09T13:58:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk3MCM3OTUyOTIyIzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-presents-data-highlighting-residual-disease-burden-in-treatment-experienced-wilson-disease-patients-and-long-term-molybdenum-safety-data-for-alxn1840-at-aasld-the-liver-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD \u2013 The Liver Meeting\u00ae 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018717"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018717\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}